Glucocorticoid-induced osteoporosis and fractures are the most frequent adverse effects of this class of medication. Recent advances in the pathophysiology, epidemiology, detection, and prevention of this complication of therapy provide hope for its amelioration in patients who require treatment with glucocorticoids. A number of effective pharmacologic agents are available and/or under study, and scientific organizations now provide guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Unfortunately, consistent application of these guidelines remains suboptimal in many practice settings.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11914-005-0024-8 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!